LEGN Legend Biotech Corp
Price Chart
Executive Summary
Legend Biotech announced it will present preliminary Phase 1 data for LB2102 (DLL3-targeted CAR-T in solid tumors) as a rapid oral presentation at ASCO 2026, along with new CARVYKTI subgroup analyses. This is a routine pipeline update with no financial data or regulatory catalysts — the LB2102 data is early-stage and the CARVYKTI presentations are incremental. The filing is a standard 6-K press release with no material financial impact.
Actionable Insight
Monitor the LB2102 Phase 1 data at ASCO on May 31 for early efficacy/safety signals in solid tumors — positive data could drive a 5-10% move. The CARVYKTI subgroup analyses are incremental and unlikely to move the stock. The investor webcast may provide qualitative commentary on commercial trends.
Key Facts
- Preliminary Phase 1 data for LB2102 (DLL3 CAR-T in SCLC/LCNEC) will be presented as a rapid oral presentation at ASCO 2026 on May 31.
- New CARTITUDE-4 cytogenetic subgroup analysis and IEC-EC incidence analysis from CARVYKTI trials will be presented as posters.
- CARVYKTI is commercially available in 18 countries and has treated over 10,000 patients.
- Legend Biotech will host an investor webcast on May 31 at 6:15 p.m. CT.
- No financial results, guidance changes, or regulatory decisions were disclosed.
Financial Impact
No financial figures disclosed. Pipeline update with no revenue or earnings impact.
Risk Factors
- LB2102 is early-stage (Phase 1) with no guarantee of efficacy in solid tumors.
- CARVYKTI safety profile includes boxed warnings for CRS, neurotoxicity, and secondary malignancies — any new safety signals at ASCO could be negative.
- No financial data or guidance in this filing — limited near-term catalyst.
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003622 |
| Document: f6k_052126.htm | 0001171843-26-003622 |
| Document: 0001171843-26-003622-index-headers.html | 0001171843-26-003622 |
| Document: 0001171843-26-003622-index.html | 0001171843-26-003622 |
| Document: 0001171843-26-003622.txt | 0001171843-26-003622 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 14, 2026
1d ago
|
Press Release
| — | awaiting T+1 | — | — |
|
Jun 2, 2026
12d ago
|
6-K
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $35.87 (−1.13%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $36.28 $35.98 | ▼ −0.83% | ▼ −0.13% | $35.87 (−1.13%) |
|
Jun 1, 2026
13d ago
|
6-K
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $35.87 (+40.61%) |
|
Jun 1, 2026
13d ago
|
Press Release
| $25.51 $36.28 | ▲ +42.22% | ▲ +42.07% | $35.87 (+40.61%) |
|
May 21, 2026
24d ago
|
6-K
| $29.37 $29.53 | ▲ +0.54% | ▼ −0.04% | $35.87 (+22.13%) |
|
May 21, 2026
24d ago
|
Press Release
| $29.37 $29.53 | ▲ +0.54% | ▼ −0.04% | $35.87 (+22.13%) |
|
May 12, 2026
4w ago
|
6-K
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $35.87 (+26.93%) |
|
May 12, 2026
4w ago
|
Press Release
| $28.26 $28.67 | ▲ +1.45% | ▲ +0.88% | $35.87 (+26.93%) |
|
Apr 28, 2026
6w ago
|
Press Release
| $23.56 $22.77 | ▼ −3.35% | ▼ −3.34% | $35.87 (+52.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access